Investor Statement
Access to Medicine Index
The goal of investors is to create long-term shareholder value in the companies in which they invest.
This potential is maximized by investing in well-managed, high quality companies, where the management team have considered fully the range of business risks and opportunities facing their companies,
and taken appropriate action to manage these. Alongside assessment of traditional financial risks andopportunities, there is growing recognition among the investment community of the potential for environmental, social and governance (ESG) factors to impact the financial performance of companies. Assuch, investors are also seeking for companies to demonstrate effective management of ESG factors.
We believe the issue of access to medicine in developing countries can present potentially significant
business impacts for global companies in the pharmaceutical sector. As greater emphasis is placed onaccessing new markets as a source for future industry growth, pharmaceutical companies are brought
into ever closer contact with access to medicine issues in developing countries. Mismanagement ofthese issues can impact negatively on political relationships and corporate brands and encumber
market access. On the other hand, if pharmaceutical companies act responsibly and with foresight,
commercial potential can be unlocked.
As investors, we seek assurances that the management of the companies in which we invest havefully considered the risks and opportunities of this issue, and have effective policies and processes fordealing with the challenges. By taking management of this issue into account, alongside other key ESG
and financial issues, the investment community can better assess the long-term investment value ofsuch companies. We are increasingly reviewing corporate approaches to access to medicine and associated aspects of intellectual property as a key strategic consideration in our analysis of the sector, where
this is appropriate to do so.
It is in this context that the investors listed below welcome the development of analytical tools such as
the Access to Medicine Index, which may be used by investors to assess companies’ management of theissue, based on information obtained from their reporting activities.
By our explicit inclusion in this statement, we are agreed on the following:• We believe the issue of access to medicine is potentially material to long-term shareholder value
creation, and is a potentially relevant consideration when forming views on the strategic positioningof companies in the pharmaceutical sector. We welcome the Access to Medicine ­Foundation’s efforts
to develop a credible, transparent and independent tool, which could be useful with regards to specificissue;• We consider that pharmaceutical companies have an important role to play in addressing the access tomedicine issue;• We will review and take into account the analysis generated from the Index as appropriate in the ESG
analysis we conduct on the companies we invest in;• We hope that the Index will contribute towards creating greater awareness within the industry of thisimportant issue, and act as a tool for highlighting leadership and good practice, as well as gaps andchallenges;• We will provide investor input into the evolution of the Index to ensure it considers the investment
perspective as appropriate and remains dynamic and relevant to the debate.
We would encourage other investors to join us in this statement.

SIG NATO RY I NVESTORSTOTAL ASSETS UNDER MANAGEMENT IN EXCESS OF USD 21 TRILLION
For more information please contact Suzi van Es
svanes@accesstomedicinefoundation.org+ 31 (0) 20 21 53 535

Updated September 2024

CO NTACTSInvestor

Signatory Contact

Aberdeen Standard Investments
Andrew Mason
AchmeaJeroen Wiercx
Adrian Dominican Sisters
Donna Meyer
Aegon Investment Management
Heike Cosse
Aequo and Hexavest
Arnaud Celka
Aikya Investment Management
Tom Allen
AlectaPeter Loow
AllianceBernstein
Saskia Kort-Chick
Alternative Bank Switzerland PLC
Katrin Wohlwend
American Century Investments
Guillaume Mascotto
Amundi Asset Management
Caroline Le Meaux
APG Asset Management
Els Knoope
Apostle Funds Management
Fiona Manning
ASN Beleggingsfondsen
Piet Sprengers
ASR Nederland NVJack Julicher
Asset Management One
Toru Terasawa
Auriga Partners
Jacques Chatain
Australian Ethical Investment
Stuart Palmer
Aviva Investors
Steve Waygood
AXA Investment Managers
Gilles Moec
BancoPosta Fondi S.p.A. SGR
Stefano Giuliani
BNP Paribas Investment Partners
Helena Vines Fiestas
Bon Secours Mercy HealthDonna Meyer
Boston Common Asset Management
Lauren Compere
Boston Trust Walden Company
Heidi Soumerai
Calvert Research and Management
Stuart DalheimCandriam Investors Group
Sophie Deleuze
CardanoColette Grosscurt
Castlefield Investment Partners
Mark Elliot
CCLA Investment Management
Amy Browne
Central Finance Board of the Methodist ChurchChristophe Borysiewicz
Church of Sweden
Sara Nordbrand
ClearBridge Investments
Marshall Gordon
CMA Impact Inc.
Ayo Olatunji
Coho Partners
Nimrit Kang
Columbia Threadneedle Investments
Catherine McCabe
Cometa Pension Fund
Maurizio Agazzi
ComgestSebastien Thevoux-Chabuel
Coöperatie VGZ UA
Erik Jan van Bergen
C-QUADRAT Asset Management GmbHGünther Kastner
Crédit Mutuel Asset Management
Isabelle Delattre
CZ Fund Management BV
Yvo Boon
Dana Investment Advisors
Ann Roberts
Daughters of Charity, Province of St. Louise
Donna Meyer
Decatur Capital Management, Inc.
Rosanne Lissow
Dignity HealthDonna Meyer
DNB Asset Management
Lise Børresen
Domini Impact Investments LLC
Carole Laible
ECO Advisors
Roz Yazdan
Ecofi Investissements
Francois Lett
EdenTree Investment Management
Ketan Patel
Edmond de Rothschild Asset Management (France) Adeline Salat-Baroux
EFG Asset Management
Stefano Montobbio
EGAMO
Jérôme Tendeau
EOS at Federated Hermes
Kimberley Lewis
Epworth Investment Management
Christophe Borysiewicz
EQ InvestorsLousiana Salge
Ethos
Vincent Kaufmann
Etica Sgr - Responsible Investments
Luca Mattiazzi
Fondita Fund Management Company
Janna Haahtela
Forma Futura AG
Doris Hauser
GAM Investments
Mark Harland
Greenbank
Matt Crossman
Groupama AM
Jana Celeste
Groupe MACSF
Luc Deschamps
Harmonie Mutuelle
Aurelien Bon
Hexavest
Jo-Annie Pinto
HSBC Asset Management
Christine Chow,
Ibercaja Gestión
Miriam Fernández Jiménez
ICCR
Meg Jones-Monteiro
Impax Asset Management and Pax World Funds
Evie Paterson
Indecap
Mats Lagerqvist
J. Safra Sarasin
Jullia Wittenberg
Janus Henderson
Antony Marsden
Jaza Rift Ventures
Sewu-Steve Tawia

Investor

Jennison Associates LLC
JLens Investment NetworkJoh. Berenberg, Gossler & Co. KG (­ Berenberg)
Kempen Capital Management
Kieger AG
La Banque Postale Asset Management
La Financiere de l'Echiquier
Länsförsäkringar AB
Legal & General Investment Management
Local Government Super
M&G Investments
Mercy Investment Services
Miller/Howard Investments
MirovaMitsubishi UFJ Trust and Banking Corporation
MN
NatixisNEI Investments
Ninety One
NN Investment Partners
Nomura Asset Management
Nordea Asset Management
Northwest Coalition for Responsible I­ nvestment
OFI Asset ManagementÖhmanParnassus Investments
Pax World FundsPensioenfonds Medewerkers Apotheken (PMA)
PGGM
Poste Vita S.p.A.
Quaestio Capital SGR Spa
Radicant Bank AG
RAM Active Investments SA
Redwheel
Reynders, McVeigh Capital Management, LLC
RobecoRoyal London Asset Management
Schroders
SEB Investment Management AB
SPH
SPMS
Stewart Investors
Stichting Algemeen Pensioenfonds U­ nileverNederlandStorebrand Asset Management
Sumitomo Mitsui Trust Asset Management
Swedbank Robur Fonder AB
Sycomore Asset Management
T. Rowe Price
The Congregation of St. Joseph
The Dai-ichi Life Insurance Company, Limited
The Sisters of St. Francis of Philadelphia
The Socially Responsible Investing Group of 1919
Investment Counsel
The Sustainability Group of Loring, W­ olcott &Coolidge
Tokio Marine Asset Management Co., Ltd.
Trillium Asset Management
Trinity Health
Triodos Investment Management
Trusteam Finance
Unigestion
Union Investment
United Church Funds
USS
Valori Asset Management
Vancity Investment Management
Varma Mutual Pension Insurance ­Company
Vontobel
VvAA Groep B.V.
VvAA Schadeverzekeringen N.V.
Wesleyan Group
WHEB Asset Management
Zevin Asset Management
Zürcher Kantonalbank

Signatory Contact

Linda Galsim
Rabbi Joshua Ratner
Dr. Rupini Rajagopalan
Eszter Vitorino
Panagiota Balfousia
Luisa Florez
Coline Pavot
Kristofer Dreiman
Maria Larsson Ortino
Moya Yip
Ben Constable Maxwell
Donna Meyer
Luan Steinhilber
Manon Salomez
Masahiro KatoLouis Kranenburg
Marina Iodice
Jamie Bonham
Stephanie Niven
Adrie Heinsbroek
Toshiyuki Imamura
Magdalena Kettis
Timnit Ghermay
Eric Van La Beck
Fredric Nystrom
Benjamin AllenJoe Keefe
Remco Velasquez
Rogier Snijdewind
Antonio Colombi
Mario Baronci
Eve Morelli
Cyrille Joye
Chris Anker
Maria Egan
Peter van der Werf
Ashley Claxton
Seema Suchak
Anette Andersson
Bram Stageman
Marcel Roberts
Jennifer Stephen
Willy Westerborg
Matthew Smith
Seiji Kawazoe
Pia Gisgård
Bertille Knuckey
Maria Elena Drew
Donna Meyer
Hiroko Ishii
Nora NashAlison Bevilacqua
Larisa Ruoff
Yo Mizuno
Jonas Kron
Cathy Rowan
Erik Breen
Claire Berthier
Eric Cockshutt
Dr. Henrik Pontzen
Charles Buck
Daniel Summerfield
Giancarlo Fragomeno
Kelly Hirsch
Kaisa Ojainmaa
Natalia Ernst
Christel de Groot
Christel de Groot
Milly Mcloughlin
Seb Beloe
Pat Miguel Tomaino
Dr. Jürgen Siemer
Updated September 2024